Gene · 57721
Papers4,298
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,661 to 1,680 of 4,298
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Translational Regulation by eIFs and RNA Modifications in Cancer. | Genes (Basel) | 2022 | 36360287 | PubTator, text mining | PubMed |
| Integrative Transcriptomic Analysis Identify Potential m6A Pathway-Related Drugs That Inhibit Cancer Cell Proliferation. | Genes (Basel) | 2022 | 36360248 | PubTator, text mining | PubMed |
| FTO Inhibits Epithelial Ovarian Cancer Progression by Destabilising SNAI1 mRNA through IGF2BP2. | Cancers (Basel) | 2022 | 36358640 | PubTator, text mining | PubMed |
| AI-empowered integrative structural characterization of m6A methyltransferase complex. | Cell Res | 2022 | 36357785 | PubTator, text mining | PubMed |
| The Mechanism and Role of N6-Methyladenosine (m6A) Modification in Atherosclerosis and Atherosclerotic Diseases. | J Cardiovasc Dev Dis | 2022 | 36354766 | PubTator, text mining | PubMed |
| N6 -methyladenosine-modified lncRNA ARHGAP5-AS1 stabilises CSDE1 and coordinates oncogenic RNA regulons in hepatocellular carcinoma. | Clin Transl Med | 2022 | 36354136 | PubTator, text mining | PubMed |
| m6A and miRNA jointly regulate the development of breast muscles in duck embryonic stages. | Front Vet Sci | 2022 | 36353255 | PubTator, text mining | PubMed |
| Mechanism of METTL14-mediated m6A modification in non-small cell lung cancer cell resistance to cisplatin. | J Mol Med (Berl) | 2022 | 36352154 | PubTator, text mining | PubMed |
| METTL14 is required for exercise-induced cardiac hypertrophy and protects against myocardial ischemia-reperfusion injury. | Nat Commun | 2022 | 36351918 | PubTator, text mining | PubMed |
| Intracellular and extracellular factors of colorectal cancer liver metastasis: a pivotal perplex to be fully elucidated. | Cancer Cell Int | 2022 | 36348319 | PubTator, text mining | PubMed |
| FMR1 promotes the progression of colorectal cancer cell by stabilizing EGFR mRNA in an m6A-dependent manner. | Cell Death Dis | 2022 | 36347844 | PubTator, text mining | PubMed |
| The phenotypic landscape of essential human genes. | Cell | 2022 | 36347254 | PubTator, text mining | PubMed |
| Prognostic and clinicopathological value of m6A regulators in human cancers: a meta-analysis. | Aging (Albany NY) | 2022 | 36347025 | PubTator, text mining | PubMed |
| Construction of m6A-based prognosis signature and prediction for immune and anti-angiogenic response. | Front Mol Biosci | 2022 | 36339715 | PubTator, text mining | PubMed |
| m6A-Related Genes Contribute to Poor Prognosis of Hepatocellular Carcinoma. | Comput Math Methods Med | 2022 | 36339682 | PubTator, text mining | PubMed |
| CD146 is closely associated with the prognosis and molecular features of osteosarcoma: Guidance for personalized clinical treatment. | Front Genet | 2022 | 36338992 | PubTator, text mining | PubMed |
| CircDDX17 enhances coxsackievirus B3 replication through regulating miR-1248/NOTCH receptor 2 axis. | Front Microbiol | 2022 | 36338034 | PubTator, text mining | PubMed |
| METTL3-mediated m6A modification of lnc RNA RHPN1-AS1 enhances cisplatin resistance in ovarian cancer by activating PI3K/AKT pathway. | J Clin Lab Anal | 2022 | 36336887 | PubTator, text mining | PubMed |
| Deciphering the map of METTL14-mediated lncRNA m6A modification at the transcriptome-wide level in breast cancer. | J Clin Lab Anal | 2022 | 36336884 | PubTator, text mining | PubMed |
| Epigenetic regulation of aging: implications for interventions of aging and diseases. | Signal Transduct Target Ther | 2022 | 36336680 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/57721/papers?page=84